Belief BioMed Eyes Rare Disorders With AAV-Based Gene Therapies
New Hemophilia B Results At ASH
China's Belief BioMed presented promising new Phase III results at ASH for its AAV gene therapy for hemophilia B, although the wider China CGT space continues to be dominated by oncology.
